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Inflammation is a necessary dynamic tissue response to injury or infection and
it’s resolution is essential to return tissue homeostasis and function. Defective or
dysregulated inflammation resolution contributes significantly to the pathogenesis of
many, often common and challenging to treat human conditions. The transition of
inflammation to resolution is an active process, involving the clearance of inflammatory
cells (granulocytes), a change of mediators and their receptors, and prevention of further
inflammatory cell infiltration. This review focuses on the use of cyclin dependent kinase
inhibitor drugs to pharmacologically target this inflammatory resolution switch, specifically
through inducing granulocyte apoptosis and phagocytic clearance of apoptotic cells
(efferocytosis). The key processes and pathways required for granulocyte apoptosis,
recruitment of phagocytes and mechanisms of engulfment are discussed along
with the cumulating evidence for cyclin dependent kinase inhibitor drugs as
pro-resolution therapeutics.
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NON-RESOLVING INFLAMMATION
Inflammation is a required dynamic tissue response to injury or infection that is vital for health and,
in the majority of cases, will lead to a return of tissue homeostasis (Nathan, 2002; Jones et al., 2016;
Robb et al., 2016). All organisms have innate mechanisms for dealing with invading pathogens
and tissue damage and these are complemented by adaptive immunity responses in many systems.
The responding inflammatory cells and molecular events, which preside after acute tissue damage,
act to limit further injury and orchestrate efficient inflammation resolution and restoration of
tissue function (Gilroy et al., 2004; Lawrence and Gilroy, 2007; Serhan et al., 2007; Poon et al.,
2014). Dysregulated or persistent inflammation following an insult, contributes significantly to
the pathogenesis of numerous, often common and difficult to treat conditions in human medicine
(Nathan and Ding, 2010; Mantovani et al., 2011; Headland and Norling, 2015; Robb et al., 2016).
Examples include atherosclerosis, rheumatoid arthritis, chronic obstructive pulmonary disease,
asthma, acute respiratory distress syndrome, Crohn’s disease, ulcerative colitis, glomerulonephritis,
neurodegenerative disease and multiple sclerosis, with non-resolving inflammation also implicated
in both obesity and cancer. Together, these conditions cost the healthcare system in excess of $1
trillion annually in the United States, as well as additional costs in lost productivity within the
workplace (Center for Medicare and Medicaid Services, 2016; Buttorff et al., 2017).
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Finding approaches to improve inflammation resolution has
therefore been an intense area of research, and pharmacologically
inducing the clearance of effete inflammatory cells from injured
tissue shows promise for future therapeutic application.
This review will cover the mechanisms of inflammation
resolution, focusing on granulocyte death and clearance. In
particular, how cyclin-dependent kinase inhibitor (CDKI) drugs
impact these mechanisms and their use to promote resolution.
THE TRANSITION FROM THE INITIATION
AND PROPAGATION OF INFLAMMATION
TO ITS RESOLUTION
To be able to pharmacologically induce or manipulate this
transitional stage of inflammation resolution, an understanding
of its key processes and pathways is required.
The Insult and Innate Cellular Response
The primary insult or pathogen is often first recognized by tissue
pattern recognition receptors (PRRs) on resident immune cells
(including granulocytes, macrophages, dendritic cells, and mast
cells), as well as by tissue parenchymal cells (especially epithelial
cells). Stimulation of PRRs leads to activation of inflammatory
cascades with subsequent release of mediators, including lipids
(e.g., leukotriene B4, etc.) and small peptides (e.g., interleukin
8, TNF, etc.), which act to attract and/or activate additional
immune cells. Neutrophils and eosinophils are cells of the
granulocyte lineage that can rapidly migrate and extravasate
from the circulation in response to these inflammatory cues.
Additional tissue signals also drive granulocyte recruitment
through a variety of ligand-receptor interactions, including the
FcγR, macrophage-1 antigen, formyl peptide receptor 1 (FPR1)
and 2 and the lymphocyte function–associated antigen (Mayadas
et al., 2014; Dahlgren et al., 2016). Chemokines, such as CXCL1,
CCL2, and CXCL10, are also released from tissues during
infections and in sterile injury, by dying cells (Garg et al., 2017)
leading to granulocyte recruitment.
These cells will act to contain and kill invading pathogens
through phagocytosis, exposure to phagolysosome contents
including elastase, myeloperoxidase, reactive oxygen species
and proteases (Segal, 2005; Nauseef, 2007; Nauseef and
Borregaard, 2014), and through release of extracellular traps
(netosis) (Brinkmann et al., 2004; Jorgensen et al., 2017).
In the event of sterile inflammation, responding neutrophils
will help phagocytose debris but they also have numerous
properties that can cause profound local tissue destruction with
amplification of inflammation. Neutrophil-derived hydrolytic,
oxidative, and pore-forming molecules and certain death
pathways, such as necrosis and netosis, have the potential
to exacerbate inflammation and tissue injury, resulting in
the progression from acute to chronic inflammation and
autoimmune conditions (Michlewska et al., 2007; Almyroudis
et al., 2013; Tiyerili et al., 2016; Rosales, 2018). It is
therefore crucial for granulocytes to be cleared from sites
of inflammation and infection once they become effete
(Lawrence and Gilroy, 2007; Duffin et al., 2010; Fox et al., 2010).
Far from being a passive process, the resolution of
inflammation is an active and highly regulated transition, which
is often initiated simultaneously with inflammation onset. It
allows a limited effective response, prevents further tissue damage
and allows organ repair and functional restoration (Walker et al.,
2005). The processes fundamental to inflammation resolution
include a change of several mediators and their receptors, for
example lysophosphatidylcholine and CX3CL1 released from
apoptotic cells or ATP and UTP, which bind to the P2Y2
nucleotide receptor (Lauber et al., 2003; Truman et al., 2008;
Elliott et al., 2009). Along with these example changes, the release
of lipoxins and annexin 1, which bind to the lipoxin A4 receptor
(ALX or FPR2), is another fundamental resolution process
that discontinues neutrophil diapedesis (Perretti et al., 2002).
Various specialized pro-resolution lipid mediators have been
identified, including lipoxins, protectins, and maresins (Buckley
et al., 2014). Finally, changes in cellular polarity secondary to
the redistribution of organization molecules, such as glycogen
synthase kinase-3β, Akt and protein kinase C are important
for altering many important biological processes, including
chemotaxis. Limiting further tissue neutrophil or eosinophil
infiltration is a therapeutic strategy along with inducing processes
to remove recruited or expanded inflammatory cell populations
(Hallett et al., 2008; Alessandri et al., 2013). Apoptosis of
effete inflammatory cells and their effective and timely clearance
by surrounding phagocytes is a major process responsible for
inflammation resolution (Reville et al., 2006; Serhan et al., 2007;
Norling and Perretti, 2013; Poon et al., 2014; Jones et al., 2016;
Felton et al., 2018) and this particular process can be enhanced
by CDKIs (see below).
Clearance of Granulocytes
Neutrophils and eosinophils may be eliminated from tissues
by several pathways, including reverse migration, lymphatic
drainage, exudation to the external environment or local cell
death, followed by efferocytosis. There are various forms of
local granulocyte death; apoptosis, autophagy, pyroptosis,
necrosis, necroptosis and netosis (Heasman et al., 2003;
Remijsen et al., 2011; Vanden Berghe et al., 2014) and these
can fundamentally influence the inflammatory environment
(Almyroudis et al., 2013; Gilroy and De Maeyer, 2015). For
example, delayed neutrophil apoptosis occurs in cystic fibrosis, a
chronic inflammatory lung disease, characterized by persistent,
neutrophil predominant, airway inflammation (McKeon et al.,
2008; Moriceau et al., 2010). In this pathological condition, the
absence of spontaneous neutrophil apoptosis leads to increased
neutrophil death by neutrophil extracellular trap formation
(netosis) and worsening inflammation (Gray et al., 2018).
Necrosis of inflammatory cells results in membrane integrity
loss and release of histotoxic products, such as proteases and
reactive oxygen species (Rydell-Törmänen et al., 2006a; Vanden
Berghe et al., 2014), whereas apoptosis is generally considered
a non-inflammatory form of cell death (McColl et al., 2007).
During apoptosis there is cessation of inflammatory cell secretory
competence and subsequent recognition by macrophages (Savill
and Wyllie, 1989; Whyte et al., 1993; Savill et al., 2002), which
is a key element for inflammation resolution (Thieblemont
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et al., 2018). Neutrophil apoptosis occurs and concludes rapidly
(usually <24 h ex vivo) and the process can be difficult to detect
in tissue where the apoptosis rate is high, such as in bacterial
LPS-induced acute lung injury, as well as in physiological states
(McGrath et al., 2011; Lucas et al., 2014). Driving cellular
apoptosis has been exploited for therapeutic gain, initially
in the treatment of cancers to drive tumor cell death (Green
and Walczak, 2013). More recently, driving granulocyte
apoptosis with CDKI drugs has successfully improved
the resolution of several models of acute and established
inflammation (Rossi et al., 2006).
APOPTOSIS PATHWAYS
During apoptosis, cellular connections with adjacent cells are
lost and there is marked nuclear chromatin and cytoplasmic
condensation, resulting in significantly reduced cell size.
Chromatin, along with the nucleosome, is cleaved into fragments
of approximately 180 base pairs shortly after the initiation of
cell death (Wyllie et al., 1984). The plasma membrane undergoes
blebbing, invaginations and the generation of fragmentated
apoptotic bodies, which have been visualized in vitro (Dorward
et al., 2014) and in vivo (Hochreiter-Hufford et al., 2013). There
are also numerous cellular membrane receptor, lipid and protein
changes mediating timely phagocytosis and thereby aiding the
switch of inflammation to resolution.
Apoptosis, including apoptosis of granulocytes, is an active
and tightly regulated form of programmed cell death (Kerr
et al., 1972; Jones et al., 2016). CDKIs induce granulocyte
apoptosis, which disables the inflammatory cell effector
functions, whilst maintaining membrane integrity and thereby
avoiding stimulation of the adaptive immune system and
maintaining self-tolerance (Duffin et al., 2009; Kushwah and
Hu, 2010; Arandjelovic and Ravichandran, 2015). This process
is triggered by activation of either of two pathways; the intrinsic
pathway, mediated by mitochondria and the extrinsic pathway,
mediated by cell surface death receptors. It is now known that
there is frequent crosstalk between these pathways (Leitch
et al., 2008; Poon et al., 2014), as molecules from one pathway
can affect the other (discussed further below) (Li et al., 1998;
Igney and Krammer, 2002). Both pathways activate caspases
(cysteine aspartyl-specific proteases), as it is the eventual
activation of these caspases with subsequent cleavage of cellular
substrates, that leads to the biochemical and structural changes of
apoptosis (Riley et al., 2006).
The Intrinsic Pathway
The intrinsic pathway in granulocytes is activated when pro-
apoptotic proteins of the Bcl-2 family, including Bax, Bad,
Bak and Bid, outweigh the anti-apoptotic Bcl-2 proteins,
including myeloid cell leukemia factor-1 (Mcl-1) and B
cell lymphoma-extra large (Bcl-XL). The trigger for this
includes diverse stimuli including endoplasmic reticulum stress,
DNA damage or exposure to pharmacological agents, such
as CDKIs.
Neutrophil pro-apoptotic protein expression (Bax,
Bad, and Bak) is constitutive (Moulding et al., 2001;
Cowburn et al., 2002), whereas pro-survival proteins,
or anti-apoptotic Bcl-2 family members (Mcl-1, A1,
Bcl-XL) are usually increased or maintained during
inflammation secondary to pro-survival mediators
(Chuang et al., 1998; Moulding et al., 1998; Fulop et al., 2002).
A relative reduction of translocated anti-apoptotic proteins
to mitochondria, triggers development of mitochondrial
outer membrane permeabilisation (MOMP). This allows
mitochondrial cytochrome C and other apoptogenic factors to
move into the cytosol and bind with APAF1 (apoptotic protease
activating factor-1), ATP and the inactive caspase, procaspase-9,
together termed the apoptosome. This leads to activation of
pro-caspase 9 to caspase 9 (Figure 1). Although neutrophils
have low numbers of mitochondria compared to many other cell
types, such as hepatocytes, the loss of MOMP is an important
and characteristic event of constitutive apoptosis (Maianski
et al., 2004; Tait and Green, 2010) and is induced by CDKIs
as discussed later. Interestingly, neutrophils have only trace
amounts of cytochrome C but this is still necessary for APAF-
1–dependent caspase activation (Pryde et al., 2000; Murphy
et al., 2003). As well as cytochrome C, mitochondria release
SMAC (second mitochondria-derived activator of caspases),
which likely has a pro-apoptotic action by inactivating the
inhibitor of apoptosis proteins (IAP) (Altznauer et al., 2004).
Within neutrophils, Mcl-1 is a key Bcl-2 pro-survival protein
instead of Bcl-2 or Bcl-XL (Edwards et al., 2004). In addition,
the pro-apoptotic Bcl-2 homologue, Bim, appears to be less
important in pharmacologically induced neutrophil apoptosis
(Leitch et al., 2010). Mcl-1 can be processed rapidly in the
proteasome, which gives it a very short half-life of approximately
2 h (compared to the 12 h half-life of proapoptotic proteins
Bax, Bid, and Bim). This short half-life is due to targeted
degradation of this protein by the 26S proteasome, secondary
to constitutive ubiquitination, and it is also recognized that the
PEST domains (proline, glutamic acid, serine and threonine)
contribute to this short half-life (Zhong et al., 2005). Neutrophils
are therefore exquisitely sensitive to alterations in Mcl-1 with
consequent modulation in apoptosis, which likely contributes to
the relatively selective apoptosis caused by some CDKIs.
Mcl-1 can also be upregulated or stabilized with various
factors to enhance neutrophil survival, such as hypoxia,
which delays neutrophil apoptosis by the activation of p38
MAPK signaling and induction of Mcl-1 (Leuenroth et al.,
2000). Granulocyte–macrophage colony-stimulating factor (GM-
CSF) promotes survival by enhanced Mcl-1 stability through
PI3K/Akt and p44/MEK/42ERK signaling pathways (Derouet
et al., 2004). Proteasome inhibitors, epoxomicin, lactacystin,
bortezomib, or cyclic AMP (cAMP) agonists, dibutyryl cAMP
and prostaglandin D2 and E2, delay neutrophil apoptosis (Rossi
et al., 1995; Lucas et al., 2013) and this has been shown
to be associated with Mcl-1 stabilization (Kato et al., 2006).
Finally, glucocorticoids induce eosinophil apoptosis and enhance
their uptake (Meagher et al., 1996; Liu et al., 1999), but
their impact on neutrophil apoptosis, which is generally a
retardation in apoptosis, is dependent on certain additional
environmental factors such as oxygen concentrations and
GM-CSF (Marwick et al., 2013).
Frontiers in Pharmacology | www.frontiersin.org 3 February 2019 | Volume 10 | Article 55
Cartwright et al. Inflammation Resolution With CDKIs
FIGURE 1 | Schematic diagram of intrinsic and extrinsic pathways of neutrophil apoptosis. The intrinsic pathway is instigated when apoptotic proteins outweigh
antiapoptotic proteins of the Bcl-2 family and trigger mitochondrial outer membrane permeability (MOMP). The resulting release of cytochrome C, ATP and apoptotic
protease activating factor-1 (APAF-1) activates caspase 9 and subsequently caspase 3. Mitochondria also release a second mitochondrial-derived activator of
caspases (SMAC), which inhibits the inhibitor of apoptosis (IAP) and thereby enhances apoptosis. Cyclin dependent kinase inhibitors (CDKI) down regulate Mcl-1 of
the Bcl-2 proteins, thereby initiating the first step of this pathway. The extrinsic pathway commences with ligation of a death receptor by TNF, Fas ligand or TRAIL. This
results in the generation of the death-inducing signaling complex (DISC) cascade and this causes pro-caspase 8 cleavage. Caspase 8 can activate MOMP via
cleavage and activation of Bid and can activate caspase 10, and subsequently executioner caspases, typically caspase 3.
The Extrinsic Pathway
The extrinsic “death receptor” pathway is activated by
extracellular factors, such as tumor necrosis factor (TNF),
tumor necrosis factor-alpha related apoptosis-inducing ligand
(TRAIL) and Fas ligand (Soengas et al., 1999), which bind
with their cognate receptor, resulting in receptor trimerization.
This process causes interactions of “death domains” with the
intracellular portions of these receptors, allowing an interaction
with several other proteins, such as the FADD adapter protein
and clusters of pro-caspase-8 (Ward et al., 1999). These protein
communications can lead to induction of the death-inducing
signaling complex (DISC) cascade and this results in pro-caspase
8 cleavage. Although mediator binding to TNF receptor, TRAIL
receptor and FasLreceptor are described as leading to apoptosis,
this is far from the sole action of these receptors and all have been
identified as important for many other cellular functions, such as
priming and chemotaxis (Anderson et al., 1997; Planells-Ferrer
et al., 2016). Caspase 8, as detailed above, can also trigger MOMP
via cleavage and therefore activation of one of the pro-apoptotic
mediators, Bid (BH3 interaction death agonist) and is one of
the main mechanisms of cross talk between the intrinsic and
extrinsic pathways (Li et al., 1998, Figure 1).
Activated caspase 8 results in caspase 10 activation and this is
where the 2 pathways, intrinsic and extrinsic, converge (Fox et al.,
2010). The resulting caspases cleave caspase 3, which is one of the
terminal transmitters leading to DNA fragmentation, as well as
cleavage of intracellular proteins. Additionally, there are other
“executioner caspases,” caspase 6 and caspase 7, which when
active will result in a proteolytic deluge of caspase activation
(Rathmell and Thompson, 1999).
EFFEROCYTOSIS AND THE
INFLAMMATORY SWITCH
Following the initiation of neutrophil apoptosis, it is imperative
that these cells are identified, phagocytosed and cleared from
tissue. Apoptosis leads to shutdown of the secretory capacity
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of granulocytes (Whyte et al., 1993; McColl et al., 2007) but if
they are not cleared promptly this will progress to secondary
necrosis, with membrane integrity loss and intracellular toxic
content release into the surrounding tissue. The recognition
and subsequent phagocytosis of apoptotic cells also induces
changes in the macrophage, as well as surrounding tissues (Han
et al., 2016). Efferocytosis commences the reprogramming of
inflammation toward resolution (Savill and Wyllie, 1989; Savill
et al., 2002; Poon et al., 2014) and this process can be enhanced
by CDKIs (Alessandri et al., 2011).
The phagocytosis of apoptotic cells or cell bodies is mainly
completed by professional phagocytes, such as macrophages
or dendritic cells. Multiple neighboring cell types can also
phagocytose and clear apoptotic cells. Airway epithelial cells
phagocytose apoptotic eosinophils and other apoptotic cell
bodies but do not appear to phagocytose apoptotic neutrophils
(Sexton et al., 2004; Juncadella et al., 2013). Macrophages
have been shown to influence efferocytosis by non-professional
phagocytes, through the release of insulin-like growth factor
1 (IGF-1) (Han et al., 2016). In this study macrophage IGF-1
dampened the airway epithelial cell engulfment of larger
apoptotic cells, while increasing that of microvesicles; preventing
IGF-1 signaling resulted in worse inflammation in vivo. Retinal
pigment epithelial cells are also able to efferocytose and
in physiological states engulf photoreceptor outer segments
(Finnemann et al., 1997). Hepatocytes can efficiently efferocytose
dead cells and this clearance is important both during
homeostasis and during inflammatory conditions (Davies et al.,
2018). Neutrophils are known to phagocytose cell debri and
have additionally been shown to complete efferocytosis of effete
neutrophils in a mouse LPS model of pulmonary inflammation
by electron microscopy (Rydell-Törmänen et al., 2006b).
The recognition and engulfment of apoptotic cells
involves several processes. Firstly, the dying cells release
“find me” signals, that mediate phagocyte cellular recruitment
and priming, and secondly, the non-viable cells can be
recognized by several structural and molecular changes termed
“eat me” signals.
“Find Me” Signals
These are important, particularly when neighboring cells do
not have phagocytic potential and tissue resident macrophages
or local dendritic cells are required to mediate clearance
(Ravichandran, 2003). This may be particularly important in
tissues with a relative rarity of resident phagocytes during health,
such as the lung, which has less than one alveolar macrophage
per 3 alveoli. Similarly, recruitment is important if the tissue
injury results in a reduction of tissue resident macrophages,
such as Kupffer cells following acute acetaminophen induced
injury (Zigmond et al., 2014). The signals identified include
lysophosphatidylcholine, which is released from apoptotic cells
in vitro, via caspase 3 mediated activation of the calcium-
independent phospholipase A2 (Lauber et al., 2003). A soluble
60kDa fragment of the fractalkine (CX3CL1) protein can serve
as a leukocyte find-me signal and has been shown to be released
during apoptosis (Truman et al., 2008). Sphingosine 1-phosphate
(S1P), a soluble molecule, has also been proposed as a find-
me signal. It is released during cell death when sphingosine
kinase 2 (SphK2) is cleaved in a caspase-1–dependent manner,
and is coupled to phosphatidylserine exposure (Weigert et al.,
2010). Finally, nucleotide release from apoptotic cells has also
been shown to act as phagocyte chemoattractants. ATP and UTP
released from early apoptotic cells can attract monocytes, via the
P2Y2 nucleotide receptor in vitro and in vivo (Elliott et al., 2009).
These “find me” molecules attract professional phagocytes and
monocytes and are secreted whilst the plasma membrane is still
intact and therefore prior to necrosis.
Several of these “find me” signals have yet to be confirmed
to be released from granulocytes, though specific neutrophil
upregulation of CXCR4 has been implicated in bone marrow
macrophage phagocytosis (Furze and Rankin, 2008). It is
also possible that “find me” signals are less important for
apoptotic granulocyte phagocytosis, given that the inflammatory
signals associated with granulocyte infiltration synchronously
promote recruitment and expansion of mononuclear phagocytes
(Soehnlein et al., 2008).
“Eat Me” Signals
The structural and molecular changes occurring in apoptotic
cells that aid efferocytosis include changes in oxidation state
(Slater et al., 1995; Chang et al., 1999), changes in plasma
membrane lipid configuration (Kagan et al., 2002), as well as
in cell membrane molecule expression (Morris et al., 1984;
Homburg et al., 1995). Several of these “eat-me”molecules, which
promote engulfment by the phagocyte, have been identified.
One of the key molecules expressed on apoptotic cells,
and evolutionary conserved across species, is the lipid
phosphatidylserine (Fadok et al., 1992, 1998a; Segawa and
Nagata, 2015). Phosphatidylserine (PS) is normally retained
on the surface of the plasma membrane through the actions
of scramblases and flippases but during apoptosis, scramblase
activation and flippase inactivation lead to the appearance
of PS on the outer leaflet (Bratton et al., 1997; Schlegel and
Williamson, 2001). Phospholipid scrambling is Ca2+ dependent
and supported by five transmembrane protein 16 (TMEM16)
members and Xkr protein members (Suzuki et al., 2010, 2013),
with the Xk-family protein Xkr8 mediating PS exposure during
apoptosis. PS exposure is required for appropriate uptake of
apoptotic cells (Henson et al., 2001) and phagocytes bind to PS
via several recognition mechanisms, which can vary dependent
on the phagocyte population and context.
PS can be recognized directly by several molecules including;
T-cell immunoglobulin mucin protein 4 (TIM4), brain-specific
angiogenesis inhibitor 1 (BAI1), Stabilin-2 (Stab2), the receptor
for advanced glycation end products (RAGE), triggering receptor
expressed on myeloid cells 2 (TREM-2) and CD300B. TIM4 has
been identified as a tethering protein which requires cooperation
from other molecules for apoptotic cell engulfment to proceed
(Dransfield et al., 2015). PS can also be recognized indirectly
by use of bridging molecules such as Protein S (Park et al.,
2007) and growth arrest-specific 6 (Gas6), (Nakano et al., 1997)
which bridge to the Tyro3, Axl, and MerTK (TAM) tyrosine
kinase receptors (Rothlin et al., 2015), or MFG-E8, which can
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FIGURE 2 | Schematic diagram of some of the molecules involved in phagocyte recruitment and recognition and engulfment of apoptotic cells. Fine me signals
including CX3CL1, Sphingosine 1-phosphate (S1P), nucleotides ATP and UTP and lysophosphatidylcholine attract phagocytes, along with inflammatory cytokines.
Both direct and indirect binding of phosphatidylserine on apoptotic cells by various molecules is involved in phagocyte detection of these cells and for tethering and
engulfment.
bridge to integrins αvβ3 and αvβ5 on phagocytes (Toda et al.,
2012) (Figure 2).
Numerous other molecules and receptors have been identified
as altered on apoptotic cells. These include CD47, a ligand
for signal regulatory protein α (SIRPα), reduced expression of
heavily sialylated proteins, calreticulin, annexin I, along with
mannose and fucose moieties, which have been reviewed in
depth (Barth et al., 2017). It is unknown why so many “find
me” and “eat me” signals are present, but the high number
identified could indicate a redundancy in the system or, more
likely, that molecules provide tissue-specific, cell-specific, context
and time dependent control. Some viable cells have been shown
to express low levels of PS (Barth et al., 2018), so it is not
surprising that additional molecules on viable cells have been
defined, that distinguish them from dying cells, so called “don’t
eat me” signals. CD31 (also known as platelet endothelial cell
adhesion molecule-1, PECAM-1) was identified as preventing
phagocytosis by human monocyte-derived macrophages in vitro
(Brown et al., 2002).
THE ANTI-INFLAMMATORY BENEFIT OF
APOPTOSIS AND EFFEROCYTOSIS
Clearance of apoptotic cells is crucial to maintain cellular
function under physiological and pathological conditions
(Michlewska et al., 2007) and is usually an immunologically silent
process, as it does not induce immune cell infiltration (Fadok
et al., 1998a; Ravichandran and Lorenz, 2007; Arandjelovic
and Ravichandran, 2015). The production of find me and eat
me signals not only promotes phagocyte recruitment but can
activate them and improve phagocytic capacity, for example
through upregulation of the bridging molecule MFG-E8 in
macrophages, which facilitates engulfment (Miksa et al., 2007).
These authors identified that CX3CL1 induces MFG-E8 in
macrophages in vitro and promotes phagocytosis of apoptotic
cells. Endogenous CX3CL1 falls during a rat model of sepsis and
is associated with lower MFG-E8. The authors found MFG-E8
can be rescued by injecting CX3CL1, which also improves
the sepsis.
Interaction of apoptotic cells with macrophages transforms
the macrophage secretory profile by increasing production of
anti-inflammatory signals (e.g., TGF-β and IL-10) (Voll et al.,
1997; Huynh et al., 2002), and reducing proinflammatory
mediators (e.g., IL-12, IL-1β, IL-8, GM-CSF, and TNF) (Fadok
et al., 1998b; Filardy et al., 2010). This change in cytokines is likely
to have subsequent effects on adaptive immunity as interferon-γ
(IFN-γ), which is required for cell mediated immune responses,
is induced by IL-12 but inhibited by IL-10 (Paul and Seder,
1994). Interestingly, the interaction of PS on viable monocytes,
through the protein S and Mer/Tyro3 receptor tyrosine kinase
axis, has been shown to augment inflammatory responses,
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indicating a duality of function dependent on the type of cell
presented (Barth et al., 2018).
The upregulation of alveolar macrophage PPARγ expression
and consequent proresolving cytokines has been shown in
an acute pulmonary inflammation model after instillation of
apoptotic leukocytes (Yoon et al., 2015). Tyrosine receptor
kinase Mer, has been shown to be a crucially expressed protein
for alveolar macrophage phagocytosis of apoptotic eosinophils,
and without this binding mechanism, increased inflammation,
delayed resolution and increased airway responsiveness
occur (Felton et al., 2018). Phagocytosis of damaged cells
by macrophages also prompts Wnt ligand secretion and
promotes liver regeneration in vivo (Boulter et al., 2012). Murine
macrophages have also been found to produce leukocyte
protease inhibitor through recognition and removal of
apoptotic cells, which could help to attenuate inflammation
(Odaka et al., 2003).
Overall the efferocytosis-induced substitution of
proinflammatory with anti-inflammatory mediators aids
inflammation resolution and permits tissue repair and
regeneration. Improved tissue inflammation has been
experimentally shown with enhancement of apoptotic cell
clearance in acute pulmonary injury (Moon et al., 2010)
and by induction of the STAT3–IL-10–IL-6 axis, a positive
regulator of macrophage efferocytosis, following hepatic injury
(Campana et al., 2018).
Apoptotic neutrophils also have additional beneficial effects in
inflammation. In a murine model of septic shock, administered
apoptotic neutrophils resulted in reduced proinflammatory
cytokines, suppression of further neutrophil infiltration and
decreased serum lipopolysaccharide which led to improved
survival (Ren et al., 2008). Inducing eosinophil apoptosis
has also been shown to attenuate airway inflammation in
an ovalbumin mouse model of allergic airway disease (Lucas
et al., 2015). Eosinophil apoptosis was induced by wogonin, a
flavone, via activation of caspase-3 and another study showed
granulocyte apoptosis was secondary to Mcl-1 downregulation,
similar to CDKI action (Lucas et al., 2013). Apoptotic
granulocytes, specifically neutrophils, have also been shown
to secrete lactoferrin which prevents recruitment of additional
granulocytes (Bournazou et al., 2009) thereby further mediating
inflammation resolution. Even prior to apoptosis, neutrophils
supress proinflammatory cytokine secretions in vitro from
monocyte-derived macrophages via sustained NFκB suppression
(Marwick et al., 2018).
PHARMACOLOGICAL MECHANISM OF
CDKIS
Given that apoptosis and phagocytic clearance of apoptotic
granulocytes is key for the resolution of inflammation, it
is not surprising that the mechanisms involved have been
intensely investigated. One pharmacological approach, targeting
this resolution switch, is the use of cyclin-dependent kinase
inhibitor drugs, which has been a focus of our laboratory for
several years.
Differences in the regulation of apoptotic pathways are
present across cell types; these differences can allow for selective
targeting, which is appealing where resolving inflammation is
required alongside repair and regeneration of local tissue. Several
investigations have revealed pharmacological inhibition of
cyclin-dependent kinases (CDKs) can induce selective apoptosis
of granulocytes with overall positive effects for the injured tissue.
CDKs are present in all known eukaryotes and they have
an evolutionarily conserved regulatory function on the cell
cycle. CDKs 1, 2, 3, and 4, are directly involved in cell cycle
regulation where they complex with their associated cyclin
partners during the progression of cell division, through the four
phases [G1, S, G2, M) (Vermeulen et al., 2003). Cells contain
endogenous CDKI proteins (e.g., p21 variant (v)1, p27Kip1
and cyclin-dependent kinase inhibitor 1C (p57, Kip2)] so the
cell cycling process is tightly regulated. Aberrant expression
or dysregulation of endogenous CDKs have been identified in
several types of cancer development and progression (Johnson
and Shapiro, 2010). Therefore, multiple inhibitors (CDKIs)
have been developed as potential cancer treatments (Bilgin
et al., 2017), with some of these having reached clinical trials
(Chen et al., 2014).
Since the discovery that neutrophils and, subsequently,
eosinophils, could be driven into apoptosis by CDKIs (Rossi et al.,
2006) this has led to the investigation of their use in several
inflammatory conditions (Rossi et al., 2007). Neutrophils are
terminally differentiated cells and therefore the action of CDKIs
on their lifespan was initially surprising, especially as some
CDKs (CDK2, CDK4, and CDK6) become downregulated during
myeloid cell maturation (Klausen et al., 2004). Additionally,
when CDKIs were used on neurons, another terminally
differentiated cell type, there was the opposite effect of prolonged
cellular survival (Dhavan and Tsai, 2001) while CDKI treatment
of cardiomyocytes inhibited doxorubicin-induced apoptosis via
reduced CDK2-dependent expression of Bim (Xia et al., 2018).
It is clear from several studies that CDKIs result in neutrophil
apoptosis through down-regulation of Mcl-1, which is a key
protein regulating neutrophil apoptosis (Moulding et al., 1998;
Edwards et al., 2004; Michels et al., 2005). It has been
demonstrated that human eosinophils have CDK1,−2,−5,−7,
and−9 (Farahi et al., 2011) and neutrophils have CDK 1,
2, 4, 5, 6, 7, and 9 to various levels (Klausen et al., 2004;
Rossi et al., 2006; Leitch et al., 2012; Wang et al., 2012) with
phosphorylation of RNA polymerase II by CDKs 7 and 9
inhibited by the CDKI R-roscovitine. CDK9 has been shown
to be a key regulator of human neutrophil lifespan and it’s
decline is associated with spontaneous apoptosis (Wang et al.,
2012). CDK9 has also recently been shown to be the key CDK
governing neutrophil apoptosis and inflammation resolution in
zebrafish (Hoodless et al., 2016). This CDK is a component of
the positive transcription elongation factor complex, involved
in transcriptional regulation (Fu et al., 1999), which is required
for maintaining levels of short lived anti-apoptotic proteins,
such as Mcl-1. Neutrophil Mcl-1expression has been shown
to decline after CDK inhibition resulting in apoptosis, even
in the face of various neutrophil pro-survival factors, such as
GM-CSF (Kobayashi et al., 2005). The CDKI, purvalanol A,
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also induces neutrophil apoptosis in vitro with an associated
increase in the turnover rate of Mcl-1 (Phoomvuthisarn et al.,
2018). CDKI induced granulocyte apoptosis is also caspase
dependent, as it can be abolished by broad spectrum inhibition
of caspases (Rossi et al., 2006; Duffin et al., 2009; Leitch et al.,
2010) confirming that CDKIs act upstream of caspase activation.
R-roscovitine was shown to cause a significant induction of
neutrophil MOMP, alongside this reduction in Mcl-1 (Leitch
et al., 2012), consistent with induction of the intrinsic apoptosis
pathway. Mcl-1 was also shown to be reduced in mouse derived
HoxB8 cells during apoptosis when cultured with R-roscovitine
(Gautam et al., 2013).
PRO-RESOLUTION EFFECTS OF CDKIS
Inducing neutrophil apoptosis with CDKIs has been shown
to considerably improve the resolution of inflammation in
diverse models. Initial studies used the CDKI, R-roscovitine,
also known as seliciclib or CYC202, which inhibits multiple
enzyme targets including CDK2, CDK7 and CDK9, and is being
trailed for various viral, neoplastic and inflammatory conditions
(Diwan et al., 2004; Sadaie et al., 2004; Raje et al., 2005; Leitch
et al., 2009; Meijer et al., 2016, see Table 1). R-roscovitine
was shown to rapidly and efficiently induce caspase-dependent
eosinophil apoptosis in vitro, which was associated with down
regulation of Mcl-1 and induction of MOMP (Duffin et al.,
2009, Figure 1). R-roscovitine was also demonstrated in vitro to
override granulocyte pro-survival mediators, TNF and LPS, to
induce neutrophil apoptosis (Leitch et al., 2010). Further insight
into CDKI mechanism was also identified in this study, as NF-κB
activation and ERK activation were not directly affected during
the stimulated apoptosis, but again Mcl-1 was downregulated.
Further to the in vitro effects of R-roscovitine, this drug was
shown to enhance inflammation resolution in mouse models
of carrageenan-induced acute pleurisy, bleomycin-induced lung
inflammation and serum-induced arthritis (Rossi et al., 2006;
Leitch et al., 2008). Human eosinophils express five known
targets for R-roscovitine: CDK1,−2,−5,−7, and−9, and this drug
induced eosinophil apoptosis and overcame the anti-apoptotic
signals from GM-CSF and IL-5 in vitro (Farahi et al., 2011).
R-rocovitine, used in an ova mouse model of allergic airway
disease, resulted in apoptosis of peripheral blood and spleen-
derived eosinophils and although this drug did not modulate the
pulmonary eosinophilia (Farahi et al., 2011), a later developed
CDKI has proved successful (Alessandri et al., 2011; Felton et al.,
2014). Neutrophil apoptosis was also induced by R-roscovitine in
a zebrafish tail injurymodel, reducing inflammatory cell numbers
(Loynes et al., 2010). R-roscovitine has also been shown to
reduce glial activation, neuronal loss and neurological deficits
after brain trauma (Hilton et al., 2008) and be neuroprotective
in a model of stroke (Menn et al., 2010). In a mouse model
of systemic lupus R-roscovitine was associated with extended
mouse lifespan, reduced glomerulonephritis with diminished
proteinuria and renal damage (Zoja et al., 2007). R-roscovitine
has also been shown to have beneficial effects by blocking
leukocyte extravasation through inhibition of CDKs 5 and 9
(Berberich et al., 2011). Additional pro-resolution effects of R-
roscovitine may also be possible when combining this compound
with nitric oxide, as these hybrid compounds have increased
pro-apoptotic activity (Montanaro et al., 2013).
As granulocytes are crucial to combat infectious diseases, it
is also important to know that inducing apoptosis in the face of
infection is still beneficial. R-roscovitine, used in wild type mice
treated with antibiotics for bacterial meningitis, significantly
accelerated recovery by inducing neutrophil apoptosis. In this
elegant study, both the number and extent of measurable
hemorrhagic events and bacterial titres was reduced by the
CDKI (Koedel et al., 2009). This investigation also confirmed
that preventing neutrophil apoptosis by genetic upregulation
of Bcl-2, resulted in enhanced tissue damage and exacerbation
of meningitis. Positive effects of CDKI have also been
identified in other models of infectious conditions (Lucas et al.,
2014; Dorward et al., 2017). Lucas et al showed a CDKI,
AT7519, accelerated bacterial clearance in an established E. coli
pneumonia model and this effect on bacterial burden was shown
to not be direct, but likely secondary to neutrophil apoptosis and
cellular clearance. Similarly, Roscovitine added to the antibiotic
ceftriaxone has been shown to reduce later bacterial burden (but
enhanced early bacterial burden) in an S. pneumoniae model of
lung infection, suggesting that the timing of CDKI in infectious
disease may be critical (Hoogendijk and Roelofs, 2012).
The more recently developed CDKI, AT7519, is a competitive
inhibitor of CDK5 and CDK9, (both kinases are present in
human neutrophils) and is in clinical trials for advanced
refractory solid tumors or non-Hodgkin’s lymphoma (Leitch
et al., 2012; Chen et al., 2014). AT7519 has also been
shown to improve LPS-induced pulmonary inflammation
resolution through downregulation of Mcl-1 (Lucas et al.,
2014). Bronchoalveolar and pulmonary neutrophils were both
significantly reduced by this CDKI via induction of apoptosis
and there was improved alveolar–capillary barrier integrity,
measured by BAL IgM. AT7519-induced downregulation of
Mcl-1 was also demonstrated in this study to be critical for
enhanced inflammation resolution in vivo, as blocking the Mcl-
1 downregulation with bortezomib (a proteasomal inhibitor)
abrogated the beneficial effect on pulmonary inflammation.
AT7519 also induces concentration-dependent apoptosis of
human eosinophils in vitro with 50 times greater potency
than R-roscovitine (Alessandri et al., 2011). This CDKI,
administered systemically at the peak of pleural inflammation in
a eosinophil-dominant pleurisy model, augmented the resolution
of inflammation (Alessandri et al., 2011).
AT7519 has been shown to override the complex neutrophil
pro-survival environment from systemic sepsis induced acute
respiratory distress syndrome (ARDS). Neutrophils isolated from
ARDS patients had reduced apoptosis in line with other studies.
However, this could be overcome by treatment with AT7519,
which also led to Mcl-1 loss and caspase activation in cells
from this patient cohort (Dorward et al., 2017). Neutrophils
with delayed apoptosis from patients with cystic fibrosis, when
cultured with AT7519, showed increased apoptosis and a
resulting reduction of extracellular trap formation (Gray et al.,
2018). Roscovitine also reversed this delayed apoptosis of cystic
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TABLE 1 | A comprehensive literature summary of the main actions of CDKI drugs on inflammatory cells or inflammatory conditions/models.







Molecular Weight: 354.458 g/mol
Half Life:
30min, rat (Vita et al., 2005)
1.19 h, mice (Nutley et al., 2005)
2–5 h, man (Benson et al., 2006)
Induced caspase-dependent neutrophil apoptosis
with a corresponding down regulation of Mcl-1.







Enhance inflammation resolution in mouse models
of carrageenan-induced acute pleurisy,
bleomycin-induced lung inflammation and
serum-induced arthritis, with a decrease in
inflammatory cells and edema formation.
Mouse In vivo Lung
Joint
Reduced ex vivo T cell and B cell proliferative
responses. Reduced T-cell production of





In vitro T and B cells
Extended mouse lifespan and reduced
glomerulonephritis in a model of systemic lupus.
Mouse In vivo Kidney
Caspase-dependent eosinophil apoptosis, reduced






Accelerated recovery from Streptococcus
pneumoniae bacterial meningitis, through neutrophil




Mouse In vivo CNS
Over-rides TNF-α and LPS-induced survival to






Reversed delayed apoptosis of neutrophils from







Induced neutrophil apoptosis in a zebrafish tail injury
model, reducing inflammatory cell numbers.
Loynes et al.,
2010
Zebrafish In vivo Tail fin
[Roscovitine (Unspecified which isomer of
Roscovitine)]
Inhibited granulocyte TNF-α-evoked expression of
endothelial adhesion molecules and inhibited protein







Decreased TNF-α-evoked leukocyte adhesion and
transmigration via cremaster intravital imaging.
Mouse In vivo Muscle
Induced eosinophil apoptosis and overcame the
anti-apoptotic signals from GM-CSF and IL-5.







Resulted in apoptosis of peripheral blood and
spleen-derived eosinophils in an ova model of
allergic airway disease.
Mouse In vivo Lung, Systemic
Induced neutrophil apoptosis and MOMP, with CDK
7 and 9 inhibition of RNA polymerase II. Gene
expression of pro-survival Bcl-2 homologs were







Propelled resolution of inflammation in the
bleomycin-induced lung injury model.
Mouse In vivo Lung
Enhanced apoptosis in neutrophils and reduced
TNF-α and keratinocyte chemoattractant production
in MH-S (alveolar macrophage) and MLE-12/











Reduced neutrophil numbers in bronchoalveolar
lavage fluid during lipoteichoic acid -induced lung
inflammation and bacterial burden in an S.
pneumoniae infection. There was also a time
dependent transient increase in bacterial load.
Mouse In vivo Lung
(Continued)
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Bcl-2 strongly protected against
roscovitine-induced apoptosis in neutrophils. Loss









Inhibit human blood eosinophil exocytosis through











R-roscovitine and nitric oxide hybrid
compounds







S-roscovitine Neuroprotective in a dose-dependent manner in
two models of focal ischemia. Resulted in less









Molecular Weight: 382.245 g/mol
Half Life:
1.8 h, mice (Dolman et al., 2015)
7–10 h, man (Mahadevan et al., 2011)
Induced apoptosis in primary human eosinophils in






Resolution of allergic pleurisy by
caspase-dependent eosinophil apoptosis and
enhanced macrophage ingestion of apoptotic
eosinophils.
Mouse In vivo Lung
Induced concentration, time, and caspase
dependent human neutrophil apoptosis via Mcl-1
downregulation and over came LPS induced
survival and lipoteichoic acid and peptidoglycan
(PepG). Did not cause human macrophage






Induced caspase-dependent apoptosis and
down-regulates the key survival protein Mcl-1 in
mouse bone marrow-derived neutrophils.
Mouse Neutrophils bone
marrow derived
Improved LPS-induced pulmonary inflammation
resolution, neutrophil apoptosis and downregulation
of Mcl-1. Enhanced bacterial clearance in
established E. coli pneumonia and accelerated
resolution of infection-associated inflammation. Also
accelerated resolution of established lipoteichoic
acid/peptidoglycan mediated lung inflammation.
Mouse In vivo Lung
Inhibited human blood eosinophil exocytosis











Accelerated resolution of neutrophilic inflammation
at the wound site at 24 h post tail fin wounding by
induction of neutrophil apoptosis with no reduction




Zebrafish In vivo Tail Fin
Over came ARDS neutrophil prolonged survival to









Induced neutrophil apoptosis in control and CF
neutrophils, correcting the delayed apoptosis in CF
to that of control levels. Also reduced neutrophil







NG75 (Gray et al., 1998; Chang et al.,
1999)
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Molecular Weight: 388.9 g/mol
Induced neutrophil apoptosis with increased Mcl-1











Molecular Weight: 401.843 g/mol
Increased neutrophil apoptosis and declined Mcl-1.
Accelerated resolution of neutrophilic inflammation
















Molecular weight: 319.138 g/mol







Resolved inflammation in the bleomycin-induced
lung injury model. Reduced neutrophils in BAL with
no detrimental effect on macrophage numbers.
Leitch et al.,
2012
Mouse In vivo Lung
(Continued)
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(And CDK1- and CDK4-selective
inhibitors).
Attenuated neuronal cell death, decreased microglial
activation and microglial-dependent neurotoxicity in
primary cortical microglia and neuronal cultures.
Hilton et al.,
2008




Decreased brain lesion volume by 37%. Reduced
glial activation, neuronal loss and neurological
deficits after traumatic brain injury.
Rat In vivo Brain
Purvalanol A Attenuated neuronal cell death. Rat In vitro Cortical
microglia
Flavopiridol Inhibited CDK9, protected human primary
chondrocytes and cartilage explants from the









Additional relevant, non-chemotherapy related actions of CDKIs are also detailed.
fibrosis neutrophils in vitro (Moriceau et al., 2010). AT7519
has also been shown to enhance inflammation resolution by
neutrophil apoptosis in a zebrafish model of tail fin injury and
this process was dependent on CDK9 reduction (Hoodless et al.,
2016). Finally, CDK9 inhibition by flavopiridol has also been
shown to protect human primary chondrocytes and cartilage
explants from the catabolic effects of proinflammatory cytokines
(Yik et al., 2014).
CDKI IMPACT ON EFFEROCYTOSIS AND
RESOLVING INFLAMMATION
It is crucial that efferocytosis continues after treatment
with CDKI, especially as there are increased number of
apoptotic neutrophils and progression to necrosis will occur
if these effete cells are not engulfed. AT7519, used at
concentrations that induce neutrophil apoptosis, does not
result in monocyte-derived macrophage apoptosis in vitro,
though does cause a concentration dependent reduction of
Mcl-1. Importantly, AT7519 did not reduce the percentage
of phagocyting macrophages in vitro (Lucas et al., 2014)
and in another study, R-roscovitine was shown to enhance
phagocytic clearance of eosinophils by macrophages (Farahi
et al., 2011). The efficiency of efferocytosis was also shown to
be improved in the LPS and pneumonia models in this same
study, and in a pleurisy mouse model (Alessandri et al., 2011),
an effect likely dependent on enhanced granulocyte apoptosis.
Many inflammatory conditions have defects in macrophage
phagocytosis or a saturation of this process (Schrijvers et al.,
2005; Morimoto et al., 2012; Barnawi et al., 2017; Bukong
et al., 2018). Therefore, the effects of additional granulocyte
apoptosis, or direct effects of CDKIs in these conditions, need
to be investigated and carefully counterbalanced with available
engulfment capacity. If not, there is the potential for additional
progression to necrosis with possible detrimental consequences.
However, whether necrosis of apoptotic neutrophils (secondary
necrosis) is as inflammatory as primary necrosis is relatively
understudied, but LL-37-induced neutrophil secondary necrosis
was shown not to be proinflammatory to macrophages (Li et al.,
2009). Saturation of efferocytosis can also provide further anti-
inflammatorymacrophage phenotypes, such as the pro-resolving,
CD11blow subtype identified during the resolution of murine
peritonitis (Schif-Zuck et al., 2011), but this effect of CDKIs
remains unexplored in vivo.
Selective and low doses of CDKIs may impact many other
cell types, including those in the surrounding tissues after
injury. Whether CDKIs, by effects on cell cycle progression, also
interfere with the cellular proliferation and subsequent tissue
repair after injury, is an area for further work (Rossi et al., 2006;
Alessandri et al., 2011; Lucas et al., 2014).
FUTURE STUDIES WITH CDKIS AND
COMPLICATION CONSIDERATIONS
CDKIs have been utilized in clinical trials to treat human cancer
but have not yet been fully trialed in human inflammatory
conditions, other than the treatment of patient cells ex vivo
(Dorward et al., 2017). Given that certain CDKIs have been
approved for human trials and their side effect profiles are
known, it is not inconceivable to consider these as future
potential therapeutic avenues for non-resolving inflammation or
to expedite recovery of acute inflammatory conditions. There
are still several unexplored inflammatory conditions, occurring
in various organs/systems, including chronic disorders, where
manipulation of granulocyte apoptosis may have beneficial
effects. Ensuring a selectivity for granulocyte apoptosis in
these established inflammation models, where there is pre-
existing damaged tissue, will also be important. Therefore,
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work is indicated to establish the breadth of CDKI granulocyte
manipulation that is both possible and beneficial.
There are also other inflammation resolving actions of CDKIs
that could be explored further. These include phagolysosome
acidification in alveolar macrophage from patients with cystic
fibrosis, lymphocyte modification and potential analgesic
properties, which are reviewed in detail by Meijer et al. (2016).
Lastly, an area remaining unexplored with regards to CDKI, is
the potential to pharmacologically harness multiple pathways of
the inflammation resolving switch synergistically. For example,
it has been shown that proresolving lipids can improved
phagocytosis, and an additional form of neutrophil apoptosis,
so called “phagocytosis-induced apoptosis” (Serhan et al., 2007;
Kebir et al., 2012). Glucocorticoids have also been shown
to increase macrophage efferocytosis of apoptotic neutrophils,
and in vitro and this did not result in proinflammatory
secretory responses by the macrophages (Liu et al., 1999;
Heasman et al., 2003). There are several other pathways that
are amenable to pharmacological targeting and the multimodal
approach, particularly of provoking granulocyte apoptosis in
combination with enhancing efferocytosis efficiency is an area of
exciting potential.
SUMMARY
As indicated above, as well as being potential anti-cancer drugs,
CDKIs have repeatedly been shown to expediate the resolution
process of many inflammatory diseases and injury models by
promoting granulocyte apoptosis in vitro and in vivo. The
mechanisms by which apoptosis is induced in granulocytes are
consistently highlighted as that of the caspase dependent intrinsic
pathway through Mcl-1 reduction and increased mitochondrial
membrane potential. CDK9 has also been demonstrated to be
the critical target of CDKIs in inducing neutrophil apoptosis.
At the CDKI concentrations used in these studies, other
non-granulocyte cells are not reported to undergo apoptosis
and indeed some other cell types are protected by CDKIs.
Efferocytosis, a required component of resolution, particularly
with increased cellular apoptosis, is unaffected or in some
models, improved. Therefore, CDKI drugs show promise for the
treatment of a number of inflammatory conditions by driving
granulocyte apoptosis and enhancing inflammation resolution.
It should also be noted that in several studies using various
preclinical models of inflammatory diseases, CDKI drugs show
benefits that may involve other, less defined, anti-inflammatory
mechanisms of action (Clough, 2002; Zoja et al., 2007; Sekine
et al., 2008; Meijer et al., 2016). The work detailed here indicates
an exciting avenue for therapeutic development and opens
opportunities for additional studies to establish the breadth of
CDKI applications.
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